NAE modulators: A potential therapy for gastric carcinoma

Qi Liang1, Maoyu Liu2, Jian Li3

  • 1College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China.

Insights

Neural precursor cell expressed developmentally downregulated protein-8 (NEDD8) activating enzyme (NAE) is a key target for anti-cancer drugs. NAE modulators show therapeutic potential in gastric carcinoma and other solid tumors.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Neural precursor cell expressed developmentally downregulated protein-8 (NEDD8) is a ubiquitin-like protein crucial for neddylation, a post-translational modification impacting protein stability.
  • Aberrant NEDD8 activity is linked to various cancers, including gastric carcinoma.
  • NEDD8 activating enzyme (NAE) initiates the NEDD8 cascade and is a significant target for anti-tumor drug development.

Purpose of the Study:

  • To elucidate the structural characteristics, catalytic sites, and mechanism of NAE.
  • To explore the relationship between neddylation and tumors via NAE's regulation of downstream pathways.
  • To review recent NAE modulators, focusing on their discovery, structure-activity relationships, efficacy, mechanisms, and clinical research.

Main Methods:

  • Literature review of NAE structure, function, and modulators.
  • Analysis of neddylation's role in tumorigenesis, particularly gastric carcinoma.
  • Evaluation of NAE inhibitors and agonists for anti-cancer potential.

Main Results:

  • NAE's structure, catalytic site, and mechanism are detailed.
  • The link between neddylation, NAE activity, and cancer development is established.
  • Various NAE modulators demonstrate anti-tumor efficacy, with expanding applications beyond hematological malignancies.

Conclusions:

  • NAE modulators are promising therapeutic agents for solid tumors, especially gastric carcinoma.
  • Further research into NAE modulator development is warranted to address existing challenges and explore new directions.
  • Understanding NAE's role in cancer provides a basis for targeted anti-tumor drug discovery.

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
713
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
280
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
659
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
467
Gastric Motility01:16

Gastric Motility

Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
1.4K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
598